Actis Biologics' angiogenesis inhibitor awaits Phase III in India
This article was originally published in Scrip
Executive Summary
Actis Biologics, a US biotech venture technology company, is developing an angiogenesis inhibitor, angiozyme, for the treatment of colorectal cancer in India.